D
David Baltimore
Researcher at California Institute of Technology
Publications - 882
Citations - 168784
David Baltimore is an academic researcher from California Institute of Technology. The author has contributed to research in topics: RNA & Virus. The author has an hindex of 203, co-authored 876 publications receiving 162955 citations. Previous affiliations of David Baltimore include Thomas Jefferson University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
HIV-1 Messenger RNA in Peripheral Blood Mononuclear Cells as an Early Marker of Risk for Progression to AIDS
TL;DR: By quantitating HIV-1 mRNA in serial peripheral blood mononuclear cell samples collected during a longitudinal study from selected asymptomatic HIV-infected men, it is found that increased viral replication appeared to precede immunodeficiency by at least 1 to 3 years.
Journal ArticleDOI
Somatic mutation gains its place among the generators of diversity.
Journal ArticleDOI
Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents.
TL;DR: Cocapping experiments showed that the A-MuLV-specified P120 protein is weakly associated with the surface P50-related protein of lymphoid cells, but no association of P120 and P50 could be demonstrated by immunoprecipitation methods.
Journal ArticleDOI
Mechanism of RNA primer removal by the RNase H activity of avian myeloblastosis virus reverse transcriptase.
TL;DR: It appears from these results that the RNase H activity associated with the enzyme shows a preference for cutting at the junction between the RNA and DNA moieties of such complexes and therefore is ideally suited for removing RNA primers.
Journal ArticleDOI
Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1.
Ha Won Lee,Samia Q. Khan,Shehryar Jehangir Khaliqdina,Mehmet M. Altintas,Florian Grahammer,Jimmy L. Zhao,Jimmy L. Zhao,Kwi Hye Koh,Nicholas J. Tardi,Mohd Hafeez Faridi,Terese Geraghty,David Cimbaluk,Katalin Susztak,Luis F. Moita,David Baltimore,Pierre-Louis Tharaux,Tobias B. Huber,Matthias Kretzler,Markus Bitzer,Jochen Reiser,Vineet Gupta +20 more
TL;DR: It is shown that miR-146a expression levels decrease in the glomeruli of patients with type 2 diabetes, which correlates with increased albuminuria and glomerular damage, and points to ErbB4/EGFR as a novel, druggable target for therapeutic intervention, especially because several pan-ErbB inhibitors are clinically available.